# Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Source: https://onco.cc/trials/nct02174549/  
OnCo record `nct02174549` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Tirapazamine in hepatocellular carcinoma and neuroendocrine tumours, run by Teclison Ltd., now recruiting.

## Summary

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer is a phase 1/2 interventional study registered as NCT02174549 by Teclison Ltd., with 25 participants planned, started 2014-09 and due to reach its primary completion in 2028-03-31. Interventions recorded: Tirapazamine and Conventional Transarterial Embolization (TAE).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02174549
- Phase: 1/2
- Setting: Phase I Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Liver Cancer
- Sponsor: Teclison Ltd.
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT02174549: https://clinicaltrials.gov/study/NCT02174549

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)

---
JSON: https://onco.cc/api/v1/entities/nct02174549.json